Expert Opinion on Emerging Drugs

Papers
(The H4-Index of Expert Opinion on Emerging Drugs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management40
A review of phase II and III drugs for the treatment and management of endometriosis27
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder24
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia22
New drugs targeting calcitonin gene-related peptide for the management of migraines19
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?17
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review17
Emerging biological treatments for asthma15
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials15
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials14
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia14
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape13
0.020416975021362